CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Sales
Capitation revenue, net	$ 16,620,488	$ 0
SaaS revenue	1,653,806	1,585,952
Management service revenue, net	519,489	0
Total sales	18,793,783	1,585,952
Cost of sales	14,647,045	909,780
Gross profit	4,146,738	676,172
Operating expenses
Research and development	285,880	557,257
Sales and marketing	24,449	166,759
General and administrative expenses	12,177,316	3,251,353
Goodwill impairment loss	0	3,471,508
Gain on sale of assets	0	(8,395,702)
Gain on lease termination	0	(25,174)
Loss on sale of fixed assets	0	54,819
Amortization	677,168	222,032
Total operating expenses	13,164,813	(697,148)
Income (loss) from operations	(9,018,075)	1,373,320
Other income (expenses)
Loss on extinguishment of debt	0	(167,797)
Settlement payment from ACMG	522,000	0
Income from forgiveness of debt	636,807	0
Impairment of Series E investment	0	(6,402,278)
Interest income	917	1,030
Interest expense – debt obligation	(784,012)	0
Interest expense – accretion of debt discount	(6,011,071)	(335,450)
Total other income (expenses)	(5,635,359)	(6,904,495)
Loss from continuing operations	(14,653,434)	(5,531,175)
Income tax benefit – deferred	984,810	0
Loss from discontinued operations (including gain on disposal of $142,027 for the year ended December 31, 2020)	0	(118,992)
Net loss	(13,668,624)	(5,650,167)
Net income attributable to noncontrolling interest	891	0
Net income (loss) attributable to Clinigence Holdings, Inc.	$ (13,669,515)	$ (5,650,167)
Basic and fully diluted income (loss) per common share:
Continuing operations	$ (0.37)	$ (1.12)
Discontinued operations	0	(0.02)
Net income (loss) per common share	$ (0.37)	$ (1.14)
Weighted average common shares outstanding - basic and fully diluted	37,325,057	4,942,268